Plumbagin nanoparticles induce dose and pH dependent toxicity on prostate cancer cells

Current Drug Delivery

Volumn 12, Issue 6, 2015, Pages 709-716

  Nair, Harikrishnan A ^a   Snima, K S ^a   Kamath, Ravindranath C ^a   Nair, Shantikumar V ^a   Lakshmanan, Vinoth Kumar ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Biocompatibility; Nanoformulation; Plumbagin; Prostate cancer; Wound healing

Indexed keywords

NANOPARTICLE; PLUMBAGIN; ANTINEOPLASTIC AGENT; NAPHTHOQUINONE; PLANT EXTRACT;

ARTICLE; ATOMIC FORCE MICROSCOPY; BIOCOMPATIBILITY; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG FORMULATION; HEMOLYSIS ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PARTICLE SIZE; PH; PHOTON CORRELATION SPECTROSCOPY; PLANT ROOT; PLUMBAGO ZEYLANICA; PRIORITY JOURNAL; PROSTATE CANCER; SCANNING ELECTRON MICROSCOPY; SURFACE CHARGE; ZETA POTENTIAL; 3T3 CELL LINE; ANIMAL; APOPTOSIS; CHEMISTRY; COMPARATIVE STUDY; DNA FRAGMENTATION; DOSE RESPONSE; DRUG EFFECTS; MALE; MOUSE; PATHOLOGY; PLUMBAGINACEAE; PROSTATIC NEOPLASMS; TIME FACTOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MICE; NANOPARTICLES; NAPHTHOQUINONES; NIH 3T3 CELLS; PARTICLE SIZE; PLANT EXTRACTS; PLUMBAGINACEAE; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 84953390347     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/1567201812666150316150033     Document Type: Article

References (20)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J. Cancer statistics. CA Cancer J. Clin., 2009, 59, 225-249.
2. Salesi, N.; Carlini, P.; Ruggeri, E.M.; Ferretti, G.; Bria, E.; Cognetti, F. Prostate cancer: the role of hormonal therapy. J. Exp. Clin. Cancer Res., 2005, 24, 175-180.
3. Arnold, J.T.; Isaacs, J.T. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr. Relat. Cancer, 2002, 9(1), 61-73.
4. Babula, P.; Mikelova, R.; Adam, V.; Kizek, R.; Havel, L.; Sladky, Z. Naphthoquinones-Biosynthesis, Occurrence And Metabolism In Plants. Ceska Slov Farm., 2006, 55, 151-159.
5. Babula, P.; Adam, V.; Havel, L.; Kizek, R. Naphthoquinones and their pharmacological properties. Ceska Slov Farm., 2007, 56(3), 114-120.
6. Talcott, R.E.; Smith, M.T.; Giannini, D.D. Inhibition of microsomal lipid peroxidation by naphthoquinones: structure-activity relationships and possible mechanisms of action. Arch. Biochem. Biophys., 1985, 241(1), 88-94.
7. Reese, S.; Vidyasagar, A.; Jacobson, L.; Acun, Z.; Esnault, S.; Hullett, D.; Malter, J.S.; Djamali, A. The Pin 1 inhibitor juglone attenuates kidney fibrogenesis via Pin 1-independent mechanisms in the unilateral ureteral occlusion model. Fibrog Tissue Rep., 2010, 3:1.
8. Marchionatti, A.M.; Picotto, G.; Narvaez, C.J.; Welsh, J.; Tolosa de Talamoni, N.G. Antiproliferative action of menadione and 1, 25(OH)2D3 on breast cancer cells. J. Steroid. Biochem. Mol. Biol., 2009, 113(3-5), 227-232.
9. Sharma, S.; Sharma, B.K.; Prabhakar, Y.S. Juglone derivatives as antitubercular agents: a rationale for the activity profile. Eur. J. Med. Chem., 2009, 44(7), 2847-2853.
10. Sandur, S.K.; Ichikawa, H.; Sethi, G.; Ahn, K.S.; Aggarwal, B.B. Plumbagin (5-Hydroxy-2-Methyl-1, 4-Naphthoquinone) suppresses NF-KappaB activation and NF-KappaB-regulated gene products through modulation of p65 and I-kappa-B-alpha kinase activation, leading to potentiation of apoptosis induced by cytokine and Chemotherapeutic Agents. J.Biol.Chem., 2006, 281(25), 17023-17033.
11. Powolny, A.A.; Singh, S.V. Plumbagin-induced Apoptosis in human prostate cancer cells is associated with modulation of cellular redox status and generation of reactive oxygen species. Pharm. Res., 2008, 25(9), 2171-2180.
12. Hafeez, B.B.; Zhong, W.; Mustafa, A.; Fischer, J.W.; Witkowsky, O.; Verma, A.K. Plumbagin inhibits prostate cancer development in TRAMP mice via targeting PKC {varepsilon}, Stat3 and neuroendocrine markers. Carcinogenesis., 2012, 33(12), 2586-2592.
13. Hafeez, B.B.; Zhong, W.; Fischer, J.W.; Mustafaa, A.; Shic, X.; Meskea, L.; Hongd, H.; Caid, W.; Havighurste, T.; Kime, K.; Vermaa, A.K. Plumbagin, a medicinal plant (Plumbago Zeylanica)-derived 1, 4-Naphthoquinone, inhibits growth and metastasis of human prostate cancer PC-3M-luciferase cells in an orthotopic xenograft mouse model. Mol. Oncol., 2013, 7(3), 428-439.
14. Noyes, A.A.; Whitney, W.R. The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc., 1987, 19, 930-934.
15. Zhang, J.Y.; Shen, Z.J. Preparation of amorphous cefuroxime axetil, nanoparticles by controlled nanoprecipitation method without surfactants. Int. J. Pharm., 2006, 323, 153-160.
16. Wang, Z.; Chen, J.F.; Le, Y.; Shen Z.G. Preparation of ultrafine beclomethasonedipropionate drug powder by antisolvent precipitation. Ind. Eng. Chem. Res., 2007, 46, 4839-4845
17. Zahr, A.S.; Davis, C.A.; Pishko, M.V. Macrophage uptake of core-shell nanoparticles surface modified with polyethylene glycol. Langmuir, 2006, 22, 8178-8185.
18. Khanna, A.; Mahalingam, K.; Chakrabarti, D.; Periyasamy, G. Ets-1 expression and gemcitabine chemoresistance in pancreatic cancer cells. Cell. Mol Biol Lett., 2011, 16(1), 101-113.
19. Chang W. Song, W. C.; Griffin, R.; Park, J.Heon.; In: Influence of Tumor pH on Therapeutic Response, Cancer Drug Discovery and Development: Cancer Drug Resistance, Ed.; B. Teicher c Humana Press Inc., Totowa, NJ, 2006; pp. 21-43.
20. Hasegawa, N.; Mizutani, K.; Suzuki, T.; Deguchi, T.; Nozawa, Y. A comparative study of protein profiling by proteomic analysis in camptothecin-resistant PC3 and camptothecin-sensitive LNCaP human prostate cancer cells. Urol. Int., 2006, 77, 347-354.